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Summary. In the last years, the employment of ageing women is increased, and the well-being of these work-
ers, together with the prevention of chronic disabling diseases, is an issue of great importance. Moreover, as 
postmenopausal ageing is associated with the loss of bone density and consequent increased fracture risk, 
promoting bone health in these women could be the best strategy for avoiding osteoporotic fractures. We 
aimed to evaluate the effects of 3-month supplementation with a commercial antioxidant product containing 
Silica on oxidative status and bone markers in a sample of Italian female workers. Subjects were menopausal 
and osteopenic women (N=29, age 59.34±6.37, mean BMI 26.19±4.01 kg/m2). At baseline (T0) and after 
three-month treatment (T1) bone mineral density (BMD) was evaluated by phalangeal osteosonogramme-
try. Haematological, serum biochemical parameters, reactive oxygen species (ROS), total antioxidant ca-
pacity (TAC), oxydated low-density lipoproteins (oxLDL) and urinary cross-links pyridinoline (PYD) and 
deoxypyridinoline (DPD) were assessed. Parametric or non-parametric tests were performed at T0 and T1. To 
analyse the possible association between two variables a linear correlation test was performed. At T0, slightly 
high levels of ROS (86% of subjects), oxLDL (59%), Total Cholesterol (T-Chol) (90%) and LDL-Chol 
(59%) were observed, together with suboptimal or deficient 25-OH vitamin D (98%) concentrations. At 
T1, oxLDL levels and the ratio oxLDL/LDL-Chol significantly decreased (p<0.01). At T0 significant nega-
tive correlations between BMD T-score and cross-links were observed (DPD/Crea: r=-0.57, p=0.001; PYD/ 
Crea: r=-0.45, p=0.01). At T1, a significant reduction (p=0.03) was observed only for DPD (µg/L) but not for 
cross-links normalized by creatinine amounts. In conclusion 3-months Silica supplementation improves sig-
nificantly oxidative status and bone resorption markers in most postmenopausal female workers, representing 
a complementary treatment for early phases of BMD reduction. 
Keywords: osteoporosis, osteoporosis prevention, silica supplementation, female workers. 
Progress in Nutrition 2019; Vol.21, N. 4: 1052-1062      DOI: 10.23751/pn.v21i4.8739               © Mattioli 1885
O r i g i n a l  a r t i c l e s
Abbreviations
Alkaline Phosphatase: ALP, creatinine: Crea, de-
oxypyridinoline: DPD, HDL cholesterol: HDL-Chol, 
LDL cholesterol: LDL-Chol, oxidized LDL: oxLDL, 
pyridinoline: PYD, reactive oxygen species: ROS, total 
antioxidant capacity: TAC, total cholesterol: T-Chol, 
total homocysteine: tHcy, triglycerides: TGs, 25 hy-
droxy vitamin D: 25-OH vitamin D.
1Department of Preventive Medicine, Occupational Health Unit; Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy; 
2Laboratory of Clinical Chemistry and Microbiology Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy; 3Department of 
Clinical Sciences and Community Health (DISCCO), Università degli Studi di Milano, Milan, Italy - E-mail: laura.tomaino@unimi.it; 4Department of 
Biomedical and Clinical Sciences “Luigi Sacco”, Università degli Studi di Milano, Milan, Italy; 5Department of Health Science, Università degli Studi di 
Milano, Santi Paolo e Carlo, Milan, Italy; 6Department of Biomedical Science for Health, Università degli Studi di Milano, Milan, Italy; 7Department of 
Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy
Osteoporosis prevention in postmenopausal female workers: beneficial effects of silicon dietary supplementation on oxidative status. A pilot study 1053
Introduction
In many European countries, the employment of 
women aged 57-64 is increased, and the well-being of 
these workers, together with the prevention of chronic 
disabling diseases, has become a topic of great interest. 
Moreover, as postmenopausal age is associated with the 
loss of bone density due to a reduction in the estrogenic 
tone, promoting bone health in these women could be 
the best strategy for avoiding osteoporotic fractures. 
Bone tissue undergoes constant renewal, and this 
process depends on the coordinated action of osteo-
clasts, osteoblasts and osteocytes, together with differ-
ent mediators such as hormones, growth factors and 
cytokines (1). 
Osteoblasts have oestrogen-specific membrane-
receptors that act as inhibitors of interleukins and tu-
mour necrosis factor (known to cause oxidative stress). 
When oestrogenic levels decrease in menopause, bone 
reabsorption increases, as no longer counterbalanced 
by bone deposition (2). 
While osteoporosis is due to the imbalance be-
tween bone resorption and bone formation, osteopenia 
is characterized by an unbalanced metabolic-nutri-
tional-oxidative status (3,4). The former is preceded by 
the latter.
Also, osteopenia and osteoporosis are related 
with oxidative stress, defined as imbalance between 
Reactive Oxygen Species (ROS) and Total Antioxidant 
Capacity (TAC). 
As bone loss occurs insidiously and is initially 
asymptomatic, osteoporosis is often diagnosed after 
the first clinical fracture has occurred. Consequently, 
an early assessment of the individual risk for osteopo-
rosis is important to prevent the first fracture, and the 
supplementation of calcium salts, vitamin D and an-
tioxidants are suggested as preventive measures (5,6).
Moreover, the intake of bioavailable silicon (Si), 
an oligo-element positively associated with BMD in 
men and pre-menopausal women (7,8,9), might have a 
beneficial role on bone, and a protective role in athero-
sclerosis development, due to its effects on collagen-
like molecules of blood vessels, by preserving integrity 
and stability of arterial walls (10,11). 
The aim of the present pilot study was to evalu-
ate the possible beneficial effects of a commercial an-
tioxidant suspension containing Si on both BMD and 
oxidative status on a sample of osteopenic postmeno-
pausal female workers. Data were evaluated at baseline 
(T0) and after 3-month supplementation (T1). 
Materials and Methods
Subjects
This study was conducted on a sample of post-
menopausal women attending their annual health 
surveillance visit as part of a workplace health pro-
motion campaign on active ageing, organized by the 
Occupational Medicine Department, Occupational 
Unit of Clinica del Lavoro “L. Devoto”, Fondazione 
IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 
Milan (Italy) (12). 
The eligibility criteria were: menopause, de-
fined after12 months of amenorrhea following the 
final menstrual period, according to the Stages of 
Reproductive Aging Workshop (13), and osteopenia, 
defined according to the BMD T-scores (as defined in 
the Instrumental section).
Subjects with BMI>30 Kg/m2, history of current 
chronic or neoplastic disease, use of anticoagulant, es-
troprogestinic or osteoporosis therapies, regular use of 
antioxidant or other dietary supplements, where con-
sidered not eligible for the study.
The selected group comes from the sample of a 
broader observational cross-sectional study that re-
cruited 385 (291 females and 94 males, age range 
18-69 years) consecutive participants, and enrolled 
them into a periodic occupational examination pro-
gram in order to test, among other parameters, the 
seasonal variation of vitamin D status throughout the 
year in several occupational areas, according to official 
European ATECO classification (14). 
Our study sample was a heterogeneous sample rep-
resentative of indoor workers from several occupational 
areas: 52% administration, 32% trading and industry, 4% 
education, 10% healthcare, and 2% services area. 
Among the whole sample, 29 women met the eligi-
bility criteria and were enrolled in the present pilot study.
During the baseline clinical examination, all sub-
jects were asked to fill in a questionnaire on general 
health, habitual dietary intake and lifestyle (15) (i.e. 
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smoking history, alcohol consumption, occupation, ed-
ucational level and socioeconomic status), and anthro-
pometric parameters (age, height, weight and body 
mass index, BMI) were recorded.
All participants were asked to maintain their ha-
bitual lifestyle and dietary habits for the entire period 
of the supplementation. Compliance with the study 
protocol was determined by review of patient diaries 
and returned remaining supplementation at the end of 
the 3rd month.
No adverse events were observed in any partici-
pant throughout the whole study period. 
A written informed consent was signed by each 
participant. The study was conducted in conformity 
with the Declaration of Helsinki, in accordance to the 
Good Clinical Practice guidelines and was approved by 
the Human Ethic Committee of Fondazione IRCCS 
Ca’ Granda Ospedale Maggiore Policlinico, Milan, 
Italy (Registration number: 852).
Supplementation and intervention  
Participants were provided with Cellfood® Silica 
Plus (NuScience Corporation, Lancaster, CA, USA), 
a dietary supplement (118 mL per bottle) containing 
a mixture of 17 amino acids, 34 enzymes and 78 trace 
minerals suspended in aqueous solution of deuterium 
sulphate (D2SO4) together with silicon dioxide (SiO2) 
(6,6 g silicon/100g Cellfood®). The dietary supple-
ment has been offered free of charge to the subjects by 
the study group.
All women were instructed to take fifteen drops 
of the supplement in a glass of low-mineral water two 
times a day (about 4 mL per day, equal to 60 mg sili-
con/day), at least thirty minutes before breakfast in 
the morning and before dinner in the evening, for the 
three months of the study period. 
Due to the high variety of mineral waters in Italy, 
the study protocol recommended to use a commercial 
low –mineral water (fixed residue < 200 mg/L). 
Subjects’ self-reported compliance to the whole 
study period was more than 95%.
Instrumental
BMD was evaluated by phalangeal quantitative 
ultrasound (QUS) method at baseline (T0) and after 
the three-month supplementation (T1). As reported 
by several studies, QUS method (in this protocol, as-
sessed by the portable device DBM Sonic, IGEA, 
Carpi, Italy) is a relatively recent non-invasive method 
of estimating bone mineral status in some peripheral 
skeletal sites (i.e. phalanges of the hand). QUS tech-
nique is safe, easy to use, radiation-free (16). The quan-
titative ultrasound measurement was performed at the 
distal meta-diaphyseal region of the proximal phalan-
ges of fingers 2 to 5 of the hand, and the results were 
expressed as T-Score and Z-Score values. Osteopenia 
was defined for T-score value ranges from -1 to -3.2 
(16-18). The device was landed for free to check its 
feasibility for a preventive occupational campaign.
Blood Samples
At T0 and T1 blood specimens from fasting sub-
jects were collected in test tubes, either without ad-
ditives for serum lipid panel, glucose, calcium (Ca), 
phosphate (P) and total alkaline phosphatase (ALP), 
vitamin D, oxidative panel and creatinine (Crea), or 
with EDTA to prevent coagulation for complete blood 
count (CBC) and plasma total homocysteine (tHcy). 
A specimen of whole blood was immediately cen-
trifuged for Hcy assay. T0 and T1 serum and plasma 
samples were frozen and stored at – 80°C for batch 
analysis at the end of the study.
Urinary Samples
To avoid the influences of circadian rhythm, fast-
ing 2-h morning urine samples were collected from 
each subject to assess urinary cross-links (PYD and 
DPD) concentrations.
Analytical and Biochemical Analysis
T0 and T1 CBC was performed as routine samples 
on XE 2100 analyzer (Dasit, Cornaredo, Italy) at the 
Fondazione IRCCS Ca’ Granda, Ospedale Maggiore 
Policlinico, Milan (Italy) laboratory. Routine bio-
chemical parameters (serum glucose, complete lipid 
panel, creatinine, Ca, P, ALP and plasma tHcy) were 
measured by commercial assays by Modular P (Roche 
Diagnostics International Ltd, Swiss). Serum oxLDL 
concentrations were measured by a commercial en-
zyme-linked immunoabsorbent assay (oxLDL ELISA, 
Mercodia, Uppsala, Sweden) on the EASIA reader 
(Medgenix Diagnostics, Fleurus, Belgium) (19,20).
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Serum ROS levels and TAC were measured by 
spectrophotometric method using a commercial kit 
(dROMs test and OXY-Adsorbent test, respectively, 
Diacron International, Grosseto, Italy) on F.R.E.E. 
analyzer (Diacron) as previously described (21,22).
Urinary cross-links (PYD and DPD) concentra-
tions were determined by HPLC method followed 
by fluorescent detection using commercially available 
kit (PYD and DPD, Chromsystems Instruments & 
Chemicals, Munich, Germany) as previously reported 
(23). The cross-links levels are reported both as nor-
malized by creatinine (pmol/µmol), and as absolute 
concentration (µg/L). As the cut-off values in µg/L are 
not provided by the commercially available kit, we re-
ferred to those published by using a validated HPLC 
procedure using a synthesized internal standard on 
urine samples of 30 healthy, not menopausal women 
(aged 36±7.1) resulting 31.68 ±9.62 (µg/L±SD) and 
190.49±49.63 (µg/L±SD) for DPD and PYD, respec-
tively (24). Vitamin D status was evaluated measur-
ing concentrations of the circulating form 25 hydroxy 
(OH) vitamin D, using DiaSorin 25-OH Vitamin D 
TOTAL competitive chemiluminescence immunoas-
say on an automated LIASON instrument (Saluggia, 
Vercelli, Italy). Hypovitaminosis D was defined ac-
cording to the 2011 Clinical Practice Guidelines of the 
Endocrine Society, according to which 30 ng/ml is the 
minimum sufficient vitamin D level (25). 
Statistical Analysis 
Based on samples distribution, Student’s t-test 
for paired data (parametric distribution) or Wilcoxon 
test (non-parametric distribution) were performed to 
compare data before and after treatment. The possible 
association between two variables was analysed by a 
linear correlation test.
Significance was set for a p-value <0.05. Data, 
expressed as mean ± standard deviation (SD), were 
analysed by using GraphPad PRISM (version 6.3) and 
MedCalc software (26).
Results
Of the sample of 29 subjects, mean age was 59.34 
± 6.37 years old, mean BMI 26.19 ± 4.01 kg/m2, and 
mean menopausal age was 51.72± 2.53 years old. 22 
women were never-smokers, 2 smokers and 5 former-
smokers (who quit smoking for 15 years).
At T0, based on the results of the standard CBC 
panel, all women had a normal haematological profile. 
Serum 25-OH vitamin D levels (measured only 
at T0), showed a hypovitaminosys D in 98% of subjects 
(mean 25-OH vitamin D 14.6 mcg/L, range 8.9-23,3). 
Finger BMD showed a mean T-score -2.01± 0.65.
Table 1 shows the haematological and biochemi-
cal parameters of the 29 women at T0 and T1. 
At baseline, all subjects’ glycaemic profile (glucose 
and insulin concentrations) were within their reference 
range. 
As far as the lipid panel is concerned, T-Chol and 
LDL-Chol levels were elevated in 90% and 59% of 
women, respectively. HDL-Chol concentrations were 
reduced in 38% of them, while TGs levels were within 
the reference range in most of the subjects. The lipo-
protein ratio oxLDL/LDL-Chol was elevated in 55% 
of the subjects.
As regards the oxidative status, TAC was elevated 
in 93% of subjects; similarly, elevated ROS concentra-
tions were observed in the majority of the participants. 
Ox-LDL levels exceeded the cut-off value in 59% of 
them. About 50% of women showed a slight hyper-
homocysteinemia and in the 62% of them creatinine 
concentrations were slightly elevated. 
At T1, after a 3-month Cellfood® Silica Plus 
supplementation, as shown in Figure 1, no signifi-
cant change was observed for anthropometric pa-
rameters, CBC nor BMD T-Score mean values (data 
not shown). Lipid profile did not show any change, 
except the ratio oxLDL/LDL-Chol, that decreased 
significantly (p<0.01) in most of women. Among all 
the other parameters, only oxLDL levels decreased 
significantly (p<0.01). 
Table 2 shows the bone metabolism profile, where 
the cross-links values are reported both 
normalized by creatinine (pmol/µmol) and as 
their concentration (µg/L). At T0, the overall urinary 
cross-link levels were within their reference range, 
while PYD/Crea and DPD/Crea resulted altered in 
14% and 1% of women, respectively. 
A significant negative correlation between BMD 
T-score and cross-links was observed (DPD/Crea:  r=- 
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0.57, p=0.001; PYD/Crea: r=- 0.45, p=0.01). However, 
when PYD and DPD values were reported as concen-
trations (µg/L), both PYD and DPD levels exceeded 
the cut-off. Moreover, both Calcium and ALP con-
centrations were elevated in 14% of the subjects. 
Only DPD concentration (µg/L) showed a significant 
reduction (p<003), whereas no changes were observed 
for cross-links normalized by creatinine amounts. At 
T1, phosphorous level was lightly increased (p=0.05), 
whereas no change was observed for both Ca and ALP 
concentrations. 
Discussion
The present pilot study evaluated the potential 
beneficial effect of a commercially available antioxi-
dant nutritional supplement on bone metabolism and 
nutritional-oxidative status in 29 Italian osteopenic 
menopausal female workers, who attended a periodic 
occupational examination program. 
The findings of our study show that the supple-
mentation, enriched with organic Silicon in colloidal 
form (more bioavailable and easily assimilable), can 
influence the oxidative stress condition, represented by 
Table 1. Subjects’ haematological and biochemical parameters evaluated at baseline and after 3-month supplementation. 
Analytes 
(Reference Interval or Cut-off )
T0 
Mean±SD (%)• 
T1 
Mean±SD (%) •
p-value
Hb (12-16 g/dL) 13.41 ± 0.65
(0)
13.20 ± 0.72
(0)
N.S. *
HCT (%) 39.69 ± 1.88
(0)
38.98 ± 1.97
(0)
N.S. *
MCV (78-99 fL) 84.18 ± 3.70
(0)
83.77 ± 3.78
(0)
N.S. *
WBC (4-10x109/L) 6.25 ± 1.13
(0)
6.26 ± 1.23
(0)
N.S. * 
Glucose (70-110 mg/dL) 81.87 ± 6.11
(0) 
83.79 ± 7.51
(0)
N.S. *
Insulin (2.6-25 µIU/L) 8.69 ± 3.12
(0)
9.73 ± 4.50
(0)
N.S.
T-Chol (<200 mg/dL) 228.09±29.25
(90)
227.03±32.02
(79)
N.S. *
LDL-Chol (<130 mg/dL) 146.13±29.35
(59)
144.84±35.15
(62)
N.S. *
HDL-Chol (>65mg/dL) 68.25±16.22
(38)
66.13±15.20
(48)
N.S. *
TGs (<170 mg/dL) 99.62±41.09
(7)
95.28±39.32
(3)
N.S. *
TAC (>350µmolHClO/mL) 402±54.36
(7)
397.48±56.83
(17)
N.S. °
ROS (<300 U. Carr) 409.37±69.9
(90)
414.36±48.08
(97)
N.S. °
oxLDL (<70 U/L) 77.15±30.25
(59)
65.19±22.88
(28)
0.01 °
oxLDL/LDL-Chol (<0.50) 0.54±0.20
(55)
0.45±0.10
(16)
0.01 °
tHcy <10.5µmol/L 11.65±1.90
(51)
12.33±1.96
(49)
N.S. °  
Creatinine (0.5-1.0 mg/dL 1.08±0.55
(62)
0.83±0.41
(24)
0.03°
In brackets: % of subjects with values out of reference interval or cut off. (* t-test, ° Wilcoxon test).
Abbreviations: WBC: white blood cells, RBC: red blood cells, Hb: hemoglobin, MCV: mean corpuscolar volume, tHCy: total homocysteine. 
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a significant reduction of both serum oxLDL levels, 
but also bone metabolism, as showed by urinary DPD 
reduction in most of the women. 
These preliminary results point out the possible 
utility of the Silica supplement (containing silicon and 
several trace minerals as iron, copper and zinc), in the 
prevention of female workers osteopenia and in buff-
ering their oxidative status condition, a risk factor for 
various non-communicable chronic diseases. 
In the course of the whole life, bone continuously 
undergoes a process of remodeling, characterized by a 
fine balance between bone reabsorption by osteoclasts, 
and deposition by osteoblasts. When a state of imbalance 
between the two activities occurs, the resulting bone loss 
may lead to the pathological condition known as osteo-
porosis. This condition is characterized by reduced bone 
mass and density and increased fracture risk, and repre-
sents the most prevalent metabolic bone disease. 
In the last few years, the importance of workers’ 
well-being and the prevention of chronic disabling 
diseases as Public Health strategy issues, is increas-
ing. In the European countries, the workforce is aging 
rapidly in all sectors and physically demanding jobs 
becomes increasingly difficult, especially for female 
postmenopausal workers (27). Workers’ ageing will be 
accompanied by a progressive reduction in their aero-
bic fitness, muscle strength and bone density, which 
means a reduction of life quality (28). In the setting 
of Occupational Medicine, even a simple preventive 
intervention (i.e. a nutrient supplementation) in post-
menopausal female workers can led to beneficial oc-
cupational health perspectives. 
Bone matrix consists of an inorganic component 
(mostly hydroxyapatite), which provides stiffness, and 
an organic component, the collagen secreted by os-
teoblast, which supplies tensile strength, ductility and 
toughness. The collagen structural unit is stabilized by 
the formation of intra- and inter-molecular pyridin-
ium collagen cross-links such as pyridinoline (PYD) 
and deoxypyridinoline (DPD), thus allowing aggrega-
tion in fibres (29,30).
Figure 1. The box plot describes the reduction (p=0.01) in ox-
LDL levels (U/L) after treatment, compared to baseline.  
Table 2. Women’ urinary and serum markers of bone metabolism evaluated at T0 and T1.
Analytes 
(Reference Interval or Cut-off )
T0 
Mean±SD (%)•  
T1
Mean±SD (%)• 
p-value
PYD/Crea (25-83 pmol/µmol) 54.64±25.08 
(14)
55.10±16.32
(7)
N.S. °
DPD/Crea (6-23 pmol/µmol) 11,71±5,23
(1)
11,71±3,64
(0)
N.S. °
PYD (190.49±49.63 µg/L) 229.18±129.04
(23)
179.10±128.81
( 18)
N.S. °
DPD (31.68 ±9.62 µg/L) 46.21±26.73
(22)
35.61±24.38
(12 )
0.03 °
Ca (8.40-10.20 mg/dL) 9.65±0.36
(14)
9.66±0.39
(10)
N.S. *
P (2.7-4.5 mg/dL)
3.62±0.43
(0)
3.76±0.57
(3)
0.05 *
ALP(35-104 U/L) 77.90±25.81
(14)
76.28±21.00
(14)
N.S. °
In brackets: % of subjects with values out of reference interval or out of cut off. (* t-test, ° Wilcoxon test).
Abbreviations: Crea: creatinine, PYD: pyridinoline, DPD: deoxypyridinoline, Ca.calcium, P: phosphate, ALP: bone alkaline phosphatase.
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Although bone mineral density is the routine in-
dicator of bone strength in clinical practice, many oth-
ers biochemical markers of bone turnover could bet-
ter reflect the status of bone metabolism (31,32). The 
pyridinium cross-links PYD and DPD are considered 
good markers to identify an increase in bone resorption 
during metabolic bone disorders. In particular, PYD is 
the major cross-link in all connective tissues, whereas 
DPD is found in high amounts in mineralized tissues. 
For this reason, DPD is considered more specific for 
bone collagen degradation than PYD (31-34).
PYD and DPD levels are usually expressed as 
the ratio of pyridinium crosslinks to urinary creatinine 
excretion (pmol/µmol). However, as creatinine is pro-
duced from the catabolism of muscle proteins, its levels 
can be affected by various factors (i.e. lean body mass, 
derangement in muscle metabolism, high or reduced 
dietary proteins intake, physical activities) (35). Thus, 
in the present study the urinary excreted cross-links 
were evaluated both as normalized by creatinine and 
as their concentrations (µg/L) (as reported in Table 2). 
Notably, after Silicon supplementation, a signifi-
cant decrease in the excreted DPD levels was observed, 
whereas no significant differences were observed when 
the crosslinks were related to creatinine. This finding 
confirms the positive effect of the supplementation on 
bone. We did not observe a reduction in urinary PYD 
excretion; this is possibly due to the poor specificity of 
this crosslink for bone tissue, as it is distributed also in 
cartilage and synovium (31-33). 
The improvement in urinary markers can be justi-
fied by the reported action of silicon on collagen syn-
thesis and reduction of bone resorption. In vitro studies 
have shown that physiological concentration of silicon 
stimulated collagen type I synthesis, and osteoblastic 
differentiation in human osteoblast-like cells (10,11).
The present findings show that the supplemen-
tation with Cellfood® Silica Plus could act on bone 
metabolism reducing bone resorption. 
The significant association between BMD T-score 
and urinary cross-links observed at T0, but lost after 
treatment, might be due to the faster changes in the lev-
els of bone resorption markers than to the T-score mod-
ifications (probably occurring after a longer treatment). 
In addition, it is possible that the supplementa-
tion period was too short. It appears, however, that 
there was a partial reduction in some of the damag-
ing effects of osteoporosis related to the significant 
improvement in oxidative alterations, thus suggesting 
the potential use of nutraceutical treatment to reduce 
working-related complications. 
As expected, the slight increase in ROS remained 
approximately unchanged. In physiological conditions, 
ROS are produced in our body (approximately 90% at 
mitochondrial level) as the result of cellular metabo-
lism and are counterbalanced by a system of antioxi-
dant enzymes and scavenger molecules, able to prevent 
and stop the chain propagation of radical reactions. 
The balance between the ROS endogenously produced 
and their neutralisation by antioxidant defence mecha-
nisms is known as “oxidative status”. When ROS con-
centration is higher than the physiological amount, 
and TAC is insufficient to neutralise them, a condi-
tion known as “oxidative stress” is produced. This con-
dition gives rise to cellular functional and structural 
alterations that are potentially responsible for various 
diseases. Oxidative stress can be counteracted by exog-
enous antioxidant compounds able to reduce the os-
teopenic and/or osteoporosis risk (19,36). 
Also, oxidative stress is considered to be closely 
associated with osteoporosis. Under physiological con-
ditions, ROS production by osteoclasts is involved in 
bone remodeling. Post-menopausal reduction in skel-
etal mass seems to be associated with excessive osteo-
clastic activity together with decreased osteoblastic 
action; this is partially due to lower stimulatory effect 
of estrogens (molecules with antioxidant properties) or 
to an unbalanced oxidative status (ROS/TAC imbal-
ance). 
Moreover, Maziere C. et al. (37) reported a role 
for oxLDL in bone remodelling by impairing the 
Receptor Activator of Nuclear factor k B Ligand 
(RANKL), a cytokine involved in osteoclasts differen-
tiation by preventing the effect of the inorganic phos-
phate (P) released by bone resorption (38).
Brodeur et al. (39) reported that low oxLDL 
concentrations induced proliferation of osteoblasts 
whereas high levels were cytotoxic. Thus, the notewor-
thy findings of the present pilot study suggest that a 
supplementation with antioxidant could help reduce 
oxidative stress and subsequently prevent bone loss in 
postmenopausal women. 
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Our previous studies in different clinical settings, 
highlighted that elevated oxLDL concentrations can 
be a consequence of oxidative stress (19,40). Oxidized 
LDL are formed by the reaction among LDL with the 
terminal compounds deriving from the free oxygen 
radical attach on poly-unsaturated fatty acids. 
Another noteworthy point, after the three-month 
Silicon supplementation, was that the lipid panel re-
mained unaltered, except for the significant decrease in 
the oxLDL concentrations and in the oxLDL/LDL-
Chol ratio. 
Oxidized Low Density Lipoprotein cholesterol 
(oxLDL), is able to generate ROS. As well known, ox-
LDL play a major role in the formation and progres-
sion of the atherosclerotic plaque, and atherosclerosis 
is often accompanied by osteoporosis (41).
The decrease in oxLDL concentration (Table 1, 
Figure 1) might be explained by different hypotheses 
due to the silicon presence in the supplementation, as 
reported by some authors: i.e. a direct scavenger effect 
of silicon on free oxygen radicals or its collaboration 
with enzymes and/or minerals or its inhibiting action 
on the lipoxygenase activity (42), or its interaction on 
superoxide dismutase activity (43,44), but this was not 
confirmed by other authors. 
According to Pawlak et al. (45), the lipoprotein 
ratio confirms the beneficial effects of antioxidant 
in improving the risk of cardiovascular diseases. The 
oxLDL/LDL-Chol ratio can help predict the de-
gree of clinical benefit in lowering such risk (12,40). 
Moreover, these markers can be associated with good 
and balanced antioxidant conditions (TAC). 
The oxidative stress condition affects both bone 
and skeletal muscle structure, thus the beneficial an-
tioxidant effect of the silicon dietary supplementation 
could explain the significant creatinine decrease (Table 
1) (36).
As Silicon and Carbon have the same chemi-
cal affinity, we might hypothesize for SiO2 a reaction 
between SiO2 and ROS, as that reported for carbon 
dioxide (CO2) (35,42), which contrasts the formation 
of superoxyde anion-radicals (O2 -∙) by inhibiting the 
activity of NADPH-oxydase, the enzyme producing 
O2 -∙ (46). 
The several trace minerals, essential cofactors for 
enzymes involved in the synthesis of bone matrix con-
stituents, and present in Cellfood® Silica Plus, could 
explain the significant increase in phosphorus (P) lev-
els observed after supplementation (as seen in Table 2). 
The intake of bioavailable Silicon, an oligoelement, is 
positively associated with bone mineral density in men 
and pre-menopausal women, even after adjustment for 
confounding factors (7-9), and the role of silicon in 
bone formation, mainly due to its promotion of colla-
gen synthesis contributing to prolyl-hydroxylase activ-
ity, has been reported elsewhere (10,11).
Therefore, Silicon supplementation could be use-
ful as a preventive or therapeutic agent against osteo-
penia and/or osteoporosis and, in addition, might have 
a protective role in the atherosclerosis development, 
due to its effects on collagen-like molecules of the 
vasculature by preserving the integrity and stability of 
arterial walls (17).
In order to better define the women’s bone me-
tabolism status, vitamin D levels were measured only 
at baseline because the supplementation does not con-
tain this vitamin. The fat-soluble Vitamin D is needed 
for Calcium absorption and bone health. In 98% of 
the population sample, serum 25-OH vitamin D levels 
were low and at the end of the study, the subjects di-
agnosed with low vitamin D levels were supplemented 
with individual dose of vitamin according to EFSA 
protocol.
Several findings reported that vitamin D insuf-
ficiency is more prevalent than previously thought, 
particularly among the elderly, among people living in 
northern latitudes and individuals with poor nutrition. 
At least a half of the women of the general population 
present vitamin D deficiency in their midlife, and our 
findings totally agree with these figures. Consequently, 
vitamin D deficiency could contribute to the increased 
risk of osteoporosis, accelerating bone loss. 
In conclusion, the present study highlighted that 
three-months’ Cellfood® Silica Plus supplementation 
improves the oxidative status. These promising results 
are confirmed by the significant decrease in oxLDL 
levels and oxLDL/LDL-Chol ratio (a new and more 
powerful biomarker than the standard lipid assess-
ment). Notably, according to our findings, most of 
the women who took the supplement, showed a sig-
nificant decrease in the bone resorption markers and 
in oxidative parameters of lipid peroxidation over the 
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supplement period, even if it was for a limited time. 
Moreover, considering its rapid clearance, silicon 
may be a potential benefit of long-term intake with-
out excessive retention and accumulation in the body. 
Therefore, a longer silicon supplementation period 
could be suggested to obtain a greater effect and could 
represent a complementary treatment for the early 
phases of BMD reduction. 
The present study has some limitations to be 
considered. First, it has to be mentioned the reduced 
number of participants. Indeed, only 29 women met 
the T-Score criteria of osteopenia and were enrolled. 
It must be stressed, however, that this is a pilot study, 
and the promising findings should be confirmed on a 
larger population. Second, the evaluation of BMD by 
routine measurement of phalangeal osteosonogram-
metry (QUS).  In fact, belonging this study to the 
wider frame of a nutritional promotion program, it 
was necessary to identify efficient, precise, reliable, 
cheap and simple indexes applicable in clinical prac-
tice and public economic management. Dual energy 
x-ray absorptiometry (DXA) is the most commonly 
used technique for bone mineral assessment world-
wide but the subject is exposed to ionized radiation. 
However, taking measurement by DXA at femur 
and lumbar column as “gold standard”, Omodei et 
al.’s study (47) reported that DXA and QUS showed 
an agreement in 90% of cases. This means that the 
agreement between the two methodologies is very 
high. Moreover, Albanese et al.’s contribution (48) 
suggested that QUS at the phalanges may represent 
an index of bone tissue condition usable to evaluate 
the degree of bone mineralization after estrogen de-
creases in early postmenopause.
Thus, allowing Occupational and Preventive 
Medicine and Governance stakeholders to plan stra-
tegic preventive measures in order to promote female 
workers’ health and to prevent disabling chronic dis-
eases.
Achieving the goal of extended health-span in the 
setting of occupational medicine will depend on elu-
cidating and exploiting successful interactions among 
biological, psychosocial and environmental factors. 
Promoting bone health in postmenopausal female 
workers can be considered part of Public Health pri-
mary and secondary life-style preventive strategies, as 
it can lead to beneficial working health perspective, 
thus preventing morbidity and improving survival by 
avoiding osteoporotic fractures.  
The observed beneficial effects of intervention 
with nutraceutical formulations could encourage fur-
ther investigations.
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